JP2016503397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503397A5 JP2016503397A5 JP2015539720A JP2015539720A JP2016503397A5 JP 2016503397 A5 JP2016503397 A5 JP 2016503397A5 JP 2015539720 A JP2015539720 A JP 2015539720A JP 2015539720 A JP2015539720 A JP 2015539720A JP 2016503397 A5 JP2016503397 A5 JP 2016503397A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- agent
- composition
- heart failure
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002327 cardiovascular agent Substances 0.000 claims description 52
- 229940125692 cardiovascular agent Drugs 0.000 claims description 52
- 206010019280 Heart failures Diseases 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 43
- 239000003112 inhibitor Substances 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 206010020772 Hypertension Diseases 0.000 claims description 19
- 208000036142 Viral infection Diseases 0.000 claims description 19
- 230000009385 viral infection Effects 0.000 claims description 19
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 18
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 18
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 18
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 18
- 239000004004 anti-anginal agent Substances 0.000 claims description 18
- 229940124345 antianginal agent Drugs 0.000 claims description 18
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 18
- 229940127218 antiplatelet drug Drugs 0.000 claims description 18
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 18
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 18
- 239000000480 calcium channel blocker Substances 0.000 claims description 18
- 239000003246 corticosteroid Substances 0.000 claims description 18
- 239000002934 diuretic Substances 0.000 claims description 18
- 230000001882 diuretic effect Effects 0.000 claims description 18
- 239000002516 radical scavenger Substances 0.000 claims description 18
- 239000000932 sedative agent Substances 0.000 claims description 18
- 230000001624 sedative effect Effects 0.000 claims description 18
- 230000002889 sympathetic effect Effects 0.000 claims description 18
- 229940124549 vasodilator Drugs 0.000 claims description 18
- 239000003071 vasodilator agent Substances 0.000 claims description 18
- 241000208011 Digitalis Species 0.000 claims description 17
- 102000003938 Thromboxane Receptors Human genes 0.000 claims description 17
- 108090000300 Thromboxane Receptors Proteins 0.000 claims description 17
- 239000002368 cardiac glycoside Substances 0.000 claims description 17
- 229940097217 cardiac glycoside Drugs 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 17
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000002464 receptor antagonist Substances 0.000 claims description 17
- 229940044551 receptor antagonist Drugs 0.000 claims description 17
- 108091006082 receptor inhibitors Proteins 0.000 claims description 17
- 229930002534 steroid glycoside Natural products 0.000 claims description 17
- 229960000103 thrombolytic agent Drugs 0.000 claims description 17
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 claims description 15
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 claims description 15
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 14
- 208000007848 Alcoholism Diseases 0.000 claims description 12
- 201000001320 Atherosclerosis Diseases 0.000 claims description 12
- 206010013654 Drug abuse Diseases 0.000 claims description 12
- 208000030814 Eating disease Diseases 0.000 claims description 12
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 12
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 12
- 208000009525 Myocarditis Diseases 0.000 claims description 12
- 208000024799 Thyroid disease Diseases 0.000 claims description 12
- 201000007930 alcohol dependence Diseases 0.000 claims description 12
- 231100000457 cardiotoxic Toxicity 0.000 claims description 12
- 230000001451 cardiotoxic effect Effects 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 235000014632 disordered eating Nutrition 0.000 claims description 12
- 230000009395 genetic defect Effects 0.000 claims description 12
- 208000007565 gingivitis Diseases 0.000 claims description 12
- 235000003642 hunger Nutrition 0.000 claims description 12
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 12
- 208000031225 myocardial ischemia Diseases 0.000 claims description 12
- 208000008494 pericarditis Diseases 0.000 claims description 12
- 208000011117 substance-related disease Diseases 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 12
- 208000021510 thyroid gland disease Diseases 0.000 claims description 12
- 208000019553 vascular disease Diseases 0.000 claims description 12
- 210000004351 coronary vessel Anatomy 0.000 claims description 11
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 9
- 102100032752 C-reactive protein Human genes 0.000 claims description 9
- 102000004889 Interleukin-6 Human genes 0.000 claims description 9
- 108090001005 Interleukin-6 Proteins 0.000 claims description 9
- 229940100601 interleukin-6 Drugs 0.000 claims description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 9
- 101001047677 Homo sapiens Lysocardiolipin acyltransferase 1 Proteins 0.000 claims description 7
- 102100024033 Lysocardiolipin acyltransferase 1 Human genes 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 6
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 6
- 238000007634 remodeling Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 102000013394 Troponin I Human genes 0.000 claims 2
- 108010065729 Troponin I Proteins 0.000 claims 2
- 230000037351 starvation Effects 0.000 claims 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229940068811 digitalis preparation Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 229930182478 glucoside Natural products 0.000 claims 1
- 150000008131 glucosides Chemical class 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 123
- 230000001258 dyslipidemic effect Effects 0.000 description 16
- 230000002537 thrombolytic effect Effects 0.000 description 16
- -1 thrombolytics Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 15
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 208000002330 Congenital Heart Defects Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 208000013200 Stress disease Diseases 0.000 description 7
- 229940127003 anti-diabetic drug Drugs 0.000 description 7
- 239000003472 antidiabetic agent Substances 0.000 description 7
- 206010003119 arrhythmia Diseases 0.000 description 7
- 230000006793 arrhythmia Effects 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 208000028831 congenital heart disease Diseases 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 208000017169 kidney disease Diseases 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 229960005095 pioglitazone Drugs 0.000 description 7
- 229960004586 rosiglitazone Drugs 0.000 description 7
- 230000000276 sedentary effect Effects 0.000 description 7
- 201000002859 sleep apnea Diseases 0.000 description 7
- 230000000391 smoking effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- 159000000021 acetate salts Chemical class 0.000 description 3
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 3
- 102000016924 KATP Channels Human genes 0.000 description 2
- 108010053914 KATP Channels Proteins 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716867P | 2012-10-22 | 2012-10-22 | |
| US61/716,867 | 2012-10-22 | ||
| US201361822752P | 2013-05-13 | 2013-05-13 | |
| US61/822,752 | 2013-05-13 | ||
| US201361839750P | 2013-06-26 | 2013-06-26 | |
| US201361839743P | 2013-06-26 | 2013-06-26 | |
| US61/839,743 | 2013-06-26 | ||
| US61/839,750 | 2013-06-26 | ||
| PCT/US2013/066228 WO2014066419A2 (en) | 2012-10-22 | 2013-10-22 | Methods for reducing risks associated with heart failure and factors associated therewith |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018018942A Division JP2018109012A (ja) | 2012-10-22 | 2018-02-06 | 心不全関連リスクおよびそれらと関連する因子を減少させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503397A JP2016503397A (ja) | 2016-02-04 |
| JP2016503397A5 true JP2016503397A5 (cg-RX-API-DMAC7.html) | 2016-12-08 |
Family
ID=50545459
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539720A Pending JP2016503397A (ja) | 2012-10-22 | 2013-10-22 | 心不全関連リスクおよびそれらと関連する因子を減少させる方法 |
| JP2018018942A Pending JP2018109012A (ja) | 2012-10-22 | 2018-02-06 | 心不全関連リスクおよびそれらと関連する因子を減少させる方法 |
| JP2019104270A Pending JP2019194193A (ja) | 2012-10-22 | 2019-06-04 | 心不全関連リスクおよびそれらと関連する因子を減少させる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018018942A Pending JP2018109012A (ja) | 2012-10-22 | 2018-02-06 | 心不全関連リスクおよびそれらと関連する因子を減少させる方法 |
| JP2019104270A Pending JP2019194193A (ja) | 2012-10-22 | 2019-06-04 | 心不全関連リスクおよびそれらと関連する因子を減少させる方法 |
Country Status (12)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3626252A1 (en) | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| DK2961378T3 (da) | 2013-03-01 | 2019-11-25 | Stealth Biotherapeutics Corp | Fremgangsmåder til behandlingen af mitochondrisk sygdom |
| CA2916977A1 (en) * | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| WO2017180535A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| MX2018015869A (es) * | 2016-06-24 | 2019-08-12 | Univ Southern California | Analogos de peptido derivado mitocondrial codificado en la subunidad nd-dos de humanos como agentes terapeuticos para diabetes, obesidad y sus enfermedades y complicaciones asociadas. |
| US11203636B2 (en) * | 2017-02-01 | 2021-12-21 | Yale University | Treatment of existing left ventricular heart failure |
| PE20211196A1 (es) | 2018-01-05 | 2021-07-01 | Novo Nordisk As | Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion |
| KR102546547B1 (ko) | 2018-01-11 | 2023-06-22 | 삼성전자주식회사 | 보행 보조 방법 및 장치 |
| KR20220052561A (ko) | 2020-10-21 | 2022-04-28 | 장영진 | 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| CN120329388B (zh) * | 2025-04-30 | 2025-09-26 | 中日友好医院(中日友好临床医学研究所) | 一种双靶点多肽及其在心衰治疗中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US20040136991A1 (en) * | 2002-07-19 | 2004-07-15 | Abbott Biotechnology Ltd. | Treatment of anemia using TNFalpha inhibitors |
| PT1599216E (pt) * | 2003-02-04 | 2013-12-17 | Cornell Res Foundation Inc | Métodos de prevenção da transição de permeabilidade mitocondrial |
| EP1890153A1 (en) * | 2006-08-16 | 2008-02-20 | F. Hoffman-la Roche AG | Cardiac troponin as an indicator of advanced coronary artery disease |
| EP1890154B1 (en) * | 2006-08-16 | 2012-07-04 | F. Hoffmann-La Roche AG | Cardiac troponin as an indicator of advanced coronary artery disease |
| US20080318909A1 (en) * | 2007-06-14 | 2008-12-25 | Sparagna Genevieve C | Use Of Linoleic Compounds Against Heart Failure |
| CN101951936A (zh) * | 2008-02-26 | 2011-01-19 | 康奈尔大学 | 用于防止和治疗急性肾损伤的方法 |
| JP5909182B2 (ja) * | 2009-08-12 | 2016-04-26 | コーネル ユニヴァーシティー | 代謝性症候群を予防し又は治療するための方法 |
| CN102711785A (zh) * | 2009-10-05 | 2012-10-03 | 康奈尔大学 | 预防或治疗心力衰竭的方法 |
| WO2011066369A2 (en) * | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to raise albumin and/or lower crp |
| US20130190244A1 (en) * | 2009-12-31 | 2013-07-25 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
| EP3090754A1 (en) * | 2009-12-31 | 2016-11-09 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| US20130040901A1 (en) * | 2010-02-26 | 2013-02-14 | University Of Florida Research Foundation Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP3040080A1 (en) * | 2010-03-15 | 2016-07-06 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| JP2015529655A (ja) * | 2012-08-02 | 2015-10-08 | ステルス ペプチドズ インターナショナル インコーポレイテッド | アテローム性硬化症の処置方法 |
| US20130303436A1 (en) * | 2012-12-06 | 2013-11-14 | Stealth Peptides Internatioanl, Inc. | Peptide therapeutics and methods for using same |
| CA2916977A1 (en) * | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| US9884085B2 (en) * | 2013-06-26 | 2018-02-06 | Stealth Biotherapeutics Corp | Methods for the regulation of matrix metalloproteinase expression |
-
2013
- 2013-10-22 CN CN201910384895.6A patent/CN110193077A/zh active Pending
- 2013-10-22 CA CA2889155A patent/CA2889155A1/en not_active Abandoned
- 2013-10-22 KR KR1020157013559A patent/KR20160009008A/ko not_active Ceased
- 2013-10-22 EP EP24159638.6A patent/EP4397314B1/en active Active
- 2013-10-22 CN CN201380067076.XA patent/CN105050613A/zh active Pending
- 2013-10-22 AU AU2013334788A patent/AU2013334788A1/en not_active Abandoned
- 2013-10-22 EP EP21197102.3A patent/EP4005582A1/en not_active Withdrawn
- 2013-10-22 EP EP13849406.7A patent/EP2908839B1/en active Active
- 2013-10-22 BR BR112015009072A patent/BR112015009072A2/pt not_active IP Right Cessation
- 2013-10-22 US US14/437,325 patent/US20150246092A1/en not_active Abandoned
- 2013-10-22 WO PCT/US2013/066228 patent/WO2014066419A2/en not_active Ceased
- 2013-10-22 MX MX2015005102A patent/MX2015005102A/es unknown
- 2013-10-22 PE PE2015000538A patent/PE20151434A1/es not_active Application Discontinuation
- 2013-10-22 EP EP19185584.0A patent/EP3586862B1/en active Active
- 2013-10-22 JP JP2015539720A patent/JP2016503397A/ja active Pending
-
2015
- 2015-04-22 NI NI201500057A patent/NI201500057A/es unknown
-
2018
- 2018-02-06 JP JP2018018942A patent/JP2018109012A/ja active Pending
- 2018-07-19 AU AU2018206766A patent/AU2018206766A1/en not_active Abandoned
-
2019
- 2019-06-04 JP JP2019104270A patent/JP2019194193A/ja active Pending
- 2019-12-20 US US16/724,076 patent/US20200360462A1/en not_active Abandoned
-
2022
- 2022-06-13 US US17/838,766 patent/US20230190859A1/en not_active Abandoned
-
2025
- 2025-01-16 US US19/025,542 patent/US20250255929A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503397A5 (cg-RX-API-DMAC7.html) | ||
| Angeli et al. | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide | |
| Selman et al. | Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches | |
| Dagher et al. | The hepatorenal syndrome | |
| Browne et al. | Pathophysiology of pulmonary complications of acute pancreatitis | |
| Sezai et al. | Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study | |
| Ahmadi et al. | Thyroid gland dysfunction and its effect on the cardiovascular system: a comprehensive review of the literature | |
| CN103429236B (zh) | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 | |
| JP2016522196A5 (cg-RX-API-DMAC7.html) | ||
| JP2013506696A5 (cg-RX-API-DMAC7.html) | ||
| JP2022137224A (ja) | 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ | |
| JP2016511259A5 (cg-RX-API-DMAC7.html) | ||
| Møller et al. | Pathogenesis and pathophysiology of hepatorenal syndrome–is there scope for prevention? | |
| JP2005515214A5 (cg-RX-API-DMAC7.html) | ||
| Xu et al. | Protective role of AT2 and B1 receptors in kinin B2-receptor-knockout mice with myocardial infarction | |
| van der Jagt et al. | Beta-blockers in intensive care medicine: potential benefit in acute brain injury and acute respiratory distress syndrome | |
| Talabieke et al. | Arachidonic acid synergizes with aspirin preventing myocardial ischaemia–reperfusion injury and mitigates bleeding risk | |
| McBride et al. | Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management | |
| Wagenaar et al. | Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury | |
| Rosseel et al. | Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine? | |
| Morganti et al. | Aliskiren: the first direct renin inhibitor available for clinical use | |
| Kupferschmid et al. | Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy | |
| JP2008515903A5 (cg-RX-API-DMAC7.html) | ||
| Ye et al. | Inhibition of the P2X7 receptor prevents atrial proarrhythmic remodeling in experimental post-operative atrial fibrillation | |
| Cömert et al. | The effect of pentoxifylline on the healing of intestinal anastomosis in rats with experimental obstructive jaundice |